Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.
In a small randomized study, this dietary approach was associated with reduced insulin doses and treatment costs, without restricting calories or carbohydrates.
Study examines the association between initiation of GLP-1 RAs versus dipeptidyl peptidase-4 inhibitors and fragility fracture risk in adults with type 2 diabetes.
Dr. Robert Dickson presents a case involving a patient who came to his clinic asking for ‘just a cream,’ but discovered a far more serious issue upon examination.
Adding to the challenge is the current lack of widespread screening programs for early stage T1DM in the general population, making it difficult to identify all patients who may benefit from teplizumab.
